Sustainability of C-Reactive Protein Apheresis in Acute Myocardial Infarction—Results from a Supplementary Data Analysis of the Exploratory C-Reactive Protein in Acute Myocardial Infarction-1 Study
暂无分享,去创建一个
R. Kunze | C. Garlichs | H. Skarabis | A. Sheriff | J. Torzewski | F. Heigl | W. Ries
[1] M. Buerke,et al. CRP-Apherese bei akutem Myokardinfarkt bzw. COVID-19 , 2022, Medizinische Klinik - Intensivmedizin und Notfallmedizin.
[2] M. Buerke,et al. [CRP apheresis in acute myocardial infarction and COVID-19]. , 2022, Medizinische Klinik, Intensivmedizin und Notfallmedizin.
[3] P. Brunner,et al. Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons , 2022, Journal of clinical medicine.
[4] A. Hochstadt,et al. Association between C-Reactive Protein Velocity and Left Ventricular Function in Patients with ST-Elevated Myocardial Infarction , 2022, Journal of clinical medicine.
[5] D. Sorysz,et al. Mid-regional pro-adrenomedullin and lactate dehydrogenase as predictors of left ventricular remodeling in patients with myocardial infarction treated with percutaneous coronary intervention. , 2021, Polish archives of internal medicine.
[6] A. Mayr,et al. Association of C-Reactive Protein Velocity with Early Left Ventricular Dysfunction in Patients with First ST-Elevation Myocardial Infarction , 2021, Journal of Clinical Medicine.
[7] P. Nordbeck,et al. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study , 2021, Frontiers in Cardiovascular Medicine.
[8] T. Rakowski,et al. Circulating biomarkers as predictors of left ventricular remodeling after myocardial infarction , 2021, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.
[9] P. Brunner,et al. C-Reactive Protein Triggers Cell Death in Ischemic Cells , 2021, Frontiers in Immunology.
[10] A. Mayr,et al. High sensitivity C-reactive protein is associated with worse infarct healing after revascularized ST-elevation myocardial infarction. , 2020, International journal of cardiology.
[11] A. Mebazaa,et al. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2) , 2019, BMJ Open.
[12] C. Garlichs,et al. “First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction , 2018, Case reports in cardiology.
[13] S. Achenbach,et al. C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty , 2017, Archives of medical science : AMS.
[14] S. Prabhu,et al. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.
[15] E. Ohman,et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. , 2016, Journal of the American College of Cardiology.
[16] A. Arai. Healing After Myocardial Infarction: A Loosely Defined Process. , 2015, JACC. Cardiovascular imaging.
[17] Daniel C. Lee,et al. Infarct healing is a dynamic process following acute myocardial infarction , 2012, Journal of Cardiovascular Magnetic Resonance.